{"id":"tmb-001","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1331128","moleculeType":"Small molecule","molecularWeight":"240.35"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TMB-001 is being developed by Timber Pharmaceuticals as a novel topical treatment for fungal dermatological conditions. The drug is formulated to penetrate affected skin tissue and target fungal pathogens, with the goal of providing improved efficacy and safety compared to existing topical antifungals.","oneSentence":"TMB-001 is a topical antifungal agent designed to treat fungal skin infections by disrupting fungal cell membrane integrity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:38:59.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Onychomycosis (fungal nail infection)"},{"name":"Other fungal skin infections"}]},"trialDetails":[{"nctId":"NCT05295732","phase":"PHASE3","title":"The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis","status":"COMPLETED","sponsor":"Timber Pharmaceuticals Inc.","startDate":"2022-06-21","conditions":"Ichthyosis","enrollment":153},{"nctId":"NCT04154293","phase":"PHASE2","title":"A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis","status":"COMPLETED","sponsor":"Timber Pharmaceuticals Inc.","startDate":"2019-12-03","conditions":"Congenital Ichthyosis","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TMB-001","genericName":"TMB-001","companyName":"Timber Pharmaceuticals Inc.","companyId":"timber-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TMB-001 is a topical antifungal agent designed to treat fungal skin infections by disrupting fungal cell membrane integrity. Used for Onychomycosis (fungal nail infection), Other fungal skin infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}